Publications

1. Robbins HA, Alcala K, Moez EK, Guida F, Thomas S, Zahed H, et al. (2023). Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program. Ann Epidemiol. 77:1–12. https://doi.org/10.1016/j.annepidem.2022.10.014 PMID:36404465
2. Robbins HA, Ferreiro-Iglesias A, Waterboer T, Brenner N, Nygard M, Bender N, et al. (2022). Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium. J Clin Oncol. 40(31):3613–22. https://doi.org/10.1200/JCO.21.01785 PMID:35700419
3. Mariosa D, Smith-Byrne K, Richardson TG, Ferrari P, Gunter MJ, Papadimitriou N, et al. (2022). Body Size at Different Ages and Risk of 6 Cancers: A Mendelian Randomization and Prospective Cohort Study. J Natl Cancer Inst. 114(9):1296–300. https://doi.org/10.1093/jnci/djac061 PMID:35438160
4. Alcala K, Mariosa D, Smith-Byrne K, Nasrollahzadeh Nesheli D, Carreras-Torres R, Ardanaz Aicua E, et al. (2022). The relationship between blood pressure and risk of renal cell carcinoma. Int J Epidemiol. 51(4):1317–27.PMID:35312764
5. Sheikh M, Mukeriya A, Shangina O, Brennan P, Zaridze D (2021). Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality : A Prospective Cohort Study. Ann Intern Med. 174(9):1232–9. https://doi.org/10.7326/M21-0252 PMID:34310171
6. Sheikh M, Shakeri R, Poustchi H, Pourshams A, Etemadi A, Islami F, et al. (2020). Opium use and subsequent incidence of cancer: results from the Golestan Cohort Study. Lancet Glob Health. 8(5):e649–60. https://doi.org/10.1016/S2214-109X(20)30059-0 PMID:32353313
7. Moody S, Senkin S, Islam SMA, Wang J, Nasrollahzadeh D, Cortez Cardoso Penha R, et al. (2021). Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. Nat Genet. 53(11):1553–63. https://doi.org/10.1038/s41588-021-00928-6 PMID:34663923
8. Abrahão R, Perdomo S, Pinto LFR, Nascimento de Carvalho F, Dias FL, de Podestá JRV, et al.; InterCHANGE Group (2020). Predictors of Survival After Head and Neck Squamous Cell Carcinoma in South America: The InterCHANGE Study. JCO Glob Oncol. 6(6):486–99. https://doi.org/10.1200/GO.20.00014 PMID:32213095
9. Alcala N, Leblay N, Gabriel AAG, Mangiante L, Hervas D, Giffon T, et al. (2019). Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat Commun. 10(1):3407. https://doi.org/10.1038/s41467-019-11276-9 PMID:31431620
10. Alcala N, Mangiante L, Le-Stang N, Gustafson CE, Boyault S, Damiola F, et al. (2019). Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. EBioMedicine. 48:191–202. https://doi.org/10.1016/j.ebiom.2019.09.003 PMID:31648983
11. Gabriel AAG, Mathian E, Mangiante L, Voegele C, Cahais V, Ghantous A, et al. (2020). A molecular map of lung neuroendocrine neoplasms. Gigascience. 9(11):giaa112. https://doi.org/10.1093/gigascience/giaa112 PMID:33124659
12.  Ji X, Mukherjee S, Landi MT, Bosse Y, Joubert P, Zhu D, et al. (2020). Protein-altering germline mutations implicate novel genes related to lung cancer development. Nat Commun. 11(1):2220. https://doi.org/10.1038/s41467-020-15905-6 PMID:32393777
13. Pertesi M, Vallée M, Wei X, Revuelta MV, Galia P, Demangel D, et al. (2019). Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia. 33(9):2324–30. https://doi.org/10.1038/s41375-019-0452-6 PMID:30967618
14. Sheikh M, Poustchi H, Pourshams A, Etemadi A, Islami F, Khoshnia M, et al. (2019). Individual and Combined Effects of Environmental Risk Factors for Esophageal Cancer Based on Results From the Golestan Cohort Study. Gastroenterology. 156(5):1416–27. https://doi.org/10.1053/j.gastro.2018.12.024 PMID:30611753
15. Abedi-Ardekani B, Nasrollahzadeh D, Egevad L, Banks RE, Vasudev N, Holcatova I, et al.; Behnoush Abedi-Ardekani (2021). Morphological findings in frozen non-neoplastic kidney tissues of patients with kidney cancer from large-scale multicentric studies on renal cancer. Virchows Arch. 478(6):1099–107. https://doi.org/10.1007/s00428-020-02986-3 PMID:33403511
16. Kreimer AR, Ferreiro-Iglesias A, Nygard M, Bender N, Schroeder L, Hildesheim A, et al. (2019). Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium. Ann Oncol. 30(8):1335–43. https://doi.org/10.1093/annonc/mdz138 PMID:31185496
17. Ferreiro-Iglesias A, McKay JD, Brenner N, Virani S, Lesseur C, Gaborieau V, et al. (2021). Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer. Nat Commun. 12(1):5945. https://doi.org/10.1038/s41467-021-26151-9 PMID:34642315
18. Byun J, Han Y, Li Y, Xia J, Long E, Choi J, et al. (2022). Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. Nat Genet. 54(8):1167–77. https://doi.org/10.1038/s41588-022-01115-x PMID:35915169
19. Hosen MI, Sheikh M, Zvereva M, Scelo G, Forey N, Durand G, et al. (2020). Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study. EBioMedicine. 53:102643. https://doi.org/10.1016/j.ebiom.2020.102643 PMID:32081602
20. Avogbe PH, Manel A, Vian E, Durand G, Forey N, Voegele C, et al. (2019). Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer. EBioMedicine. 44:431–8. https://doi.org/10.1016/j.ebiom.2019.05.004 PMID:31122840